Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Allows Pharma To Temporarily Prioritize Reporting For COVID-19 Adverse Events

Prioritization Allowed Until The Pandemic Is Resolved

Executive Summary

Drug companies unable to continue with standard reporting of suspected adverse reactions to the EU pharmacovigilance database can temporarily prioritize their reporting activities to focus on COVID-19 related safety events.

You may also be interested in...



EMA Proposes Extending Remote QP Batch Certification Post-Pandemic

Stakeholders given one month to weigh in on proposal to allow relaxations introduced in response to COVID-19-related travel restrictions to continue on a routine basis.

COVID-19 Pandemic Pushes EU To Extend GMP/GDP Certificate Validity

As the COVID-19 pandemic continues to pose difficulties in conducting on-site inspections to check compliance with good manufacturing and distribution requirements, regulators in the EU have extended the validity of existing certificates and time-limited authorizations till the end of next year.

World’s Pharmaceutical Inspectorates Prepare For Post-Pandemic Remote Site Assessments

US, EU, global authorities share experiences, insights, advice for industry on remote alternatives even after inspectors can resume travels.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS142060

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel